Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • AMPK
    (2)
  • Adrenergic Receptor
    (2)
  • CDK
    (2)
  • Antibiotic
    (1)
  • Bcl-2 Family
    (1)
  • COX
    (1)
  • E1/E2/E3 Enzyme
    (1)
  • GSK-3
    (1)
  • Histone Demethylase
    (1)
  • Others
    (4)
TargetMol | Tags By Natures
  • Polygonum
    (1)
TargetMol | Tags By ResearchField
  • Nervous System
    (4)
Filter
Search Result
Results for "

neurodevelopmental

" in TargetMol Product Catalog.
  • Inhibitors & Agonists
    16
    TargetMol | All_Pathways
  • Natural Products
    1
    TargetMol | Natural_Products
  • Recombinant Protein
    4
    TargetMol | Recombinant_Protein
  • Isotope Products
    4
    TargetMol | Isotope_Products
  • Reference Standards
    3
    TargetMol | Standard_Products
  • Oligonucleotides
    1
    TargetMol | All_Pathways
  • PF-04885614
    T124211480833-70-2
    PF-04885614 is a potent inhibitor of NaV1.8, has potential for neurological and neurodevelopmental diseases treatment.
    • $58
    In Stock
    Size
    QTY
  • TAK-418
    T392521818252-53-7In house
    TAK-418 is a selective and orally active inhibitor of LSD1/KDM1A enzyme with an IC50 of 2.9 nM. TAK-418 unlocks abnormal epigenetic mechanisms and improves autism symptoms in models of neurodevelopmental disorders.
    • $140
    In Stock
    Size
    QTY
  • Fluparoxan hydrochloride
    T77565105227-44-9In house
    Fluparoxan hydrochloride is a highly selective and potent α2-adrenoceptor antagonist for the prevention, amelioration or treatment of neurodevelopmental disorders and neurodegenerative diseases.
    • $117
    In Stock
    Size
    QTY
  • (3aR,9aR)-Fluparoxan
    T77566105182-47-6In house
    (3aR,9aR)-Fluparoxan is a highly selective and potent adrenergic receptor α2B antagonist for the prevention, amelioration or treatment of neurodevelopmental disorders and neurodegenerative diseases.
    • $195
    In Stock
    Size
    QTY
  • NUAK1-IN-1
    T205625
    NUAK1-IN-1 (Compound 9) is an inhibitor of NUAK1 with an IC50 of 5.012 nM, as well as a CDK4 inhibitor. It is suitable for research related to cancer, neurodevelopmental disorders, and Alzheimer's disease.
    • Inquiry Price
    Inquiry
    Size
    QTY
  • NUAK1-IN-2
    T205650
    NUAK1-IN-2 (Compound 24) is an inhibitor of NUAK1 with an IC50 of 3.162 nM, as well as an inhibitor of CDK2/4/6. It is applicable in research related to cancer, neurodevelopmental disorders, and Alzheimer's disease.
    • Inquiry Price
    Inquiry
    Size
    QTY
  • ppGalNAc-T2-IN-1
    T2129701112431-86-3
    ppGalNAc-T2-IN-1 (Compound 15) is an inhibitor of polypeptide N-acetylgalactosaminyltransferase 2 (ppGalNAc-T2) with an IC50 of 7.11 μM. It is applicable for research in metabolic and neurodevelopmental disorders.
    • Inquiry Price
    10-14 weeks
    Size
    QTY
  • Plazinemdor
    T399402378285-59-5
    Plazinemdor is an NMDA receptor positive allosteric modulator with potential applications in psychiatric, neurological, neurodevelopmental disorders, and diseases of the nervous system.
      Inquiry
    • Thimerosal
      Sodium ethylmercurithiosalicylate
      T7526054-64-8
      Thimerosal is a mercury-containing vaccine preservative, which is currently considered one of the suspected causative agents of neurodevelopmental disorders.
      • $30
      In Stock
      Size
      QTY
      TargetMol | Citations Cited
    • Rugonersen sodium
      RO7248824 sodium, RG6091 sodium
      T883712591588-58-6
      Rugonersen sodium is a locked nucleic acid (LNA)-modified antisense oligonucleotide (ASO) designed to reduce the silencing of ubiquitin protein ligase E3A (UBE3A). Angelman syndrome (AS) refers to a severe neurodevelopmental disorder caused by the loss of neuronal E3 ligase UBE3A, and Rugonersen has been studied for its potential use in the treatment of AS.
      • Inquiry Price
      Inquiry
      Size
      QTY
    • Propionicacid-D5
      TMIJ-005260153-92-6
      Propionicacid-D5 is a deuterated compound of Propionicacid. Propionicacid has a CAS number of 79-09-4. Propionic acid (PA) is widely used as an antifungal agent in food. It is present naturally at low levels in dairy products and occurs ubiquitously, together with other short-chain fatty acids (SCFA), in the gastro-intestinal tract of humans and other mammals as an end-product of the microbial digestion of carbohydrates. It has significant physiological activity in animals. PA is irritant but produces no acute systemic effects and has no demonstrable genotoxic potential.Propionic aciduria is one of the most frequent organic acidurias, a disease that comprise many various disorders. The outcome of patients born with Propionic aciduria (genetic disorder) is poor intellectual development patterns, with 60% having an IQ less than 75 and requiring special education. Successful liver and/or renal transplantations, in a few patients, have resulted in better quality of life but have not necessarily prevented neurological and various visceral complications. These results emphasize the need for permanent metabolic follow-up whatever the therapeutic strategy. Decreased early mortality, less severe symptoms at diagnosis, and more favorable short-term neurodevelopmental outcome were recorded in patients identified through expanded newborn screening.
      • Inquiry Price
      7-10 days
      Size
      QTY
    • Propionic-2,2-D2 acid
      TMIJ-005419136-91-5
      Propionic-2,2-D2 acid is a deuterated compound of Propionic acid. Propionic acid has a CAS number of 79-09-4. Propionic acid (PA) is widely used as an antifungal agent in food. It is present naturally at low levels in dairy products and occurs ubiquitously, together with other short-chain fatty acids (SCFA), in the gastro-intestinal tract of humans and other mammals as an end-product of the microbial digestion of carbohydrates. It has significant physiological activity in animals. PA is irritant but produces no acute systemic effects and has no demonstrable genotoxic potential.Propionic aciduria is one of the most frequent organic acidurias, a disease that comprise many various disorders. The outcome of patients born with Propionic aciduria (genetic disorder) is poor intellectual development patterns, with 60% having an IQ less than 75 and requiring special education. Successful liver and/or renal transplantations, in a few patients, have resulted in better quality of life but have not necessarily prevented neurological and various visceral complications. These results emphasize the need for permanent metabolic follow-up whatever the therapeutic strategy. Decreased early mortality, less severe symptoms at diagnosis, and more favorable short-term neurodevelopmental outcome were recorded in patients identified through expanded newborn screening.
      • Inquiry Price
      7-10 days
      Size
      QTY
    • Thimerosal (Standard)
      TMSM-224354-64-8
      Thimerosal (Standard) is the standard substance of Thimerosal, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Thimerosal, a vaccine preservative containing mercury, is suspected to play a role in the development of neurodevelopmental disorders.
      • $36
      7-10 days
      Size
      QTY
    • Propionic-2,2-d2 Acid (Standard)
      TMSM-606619136-91-5
      Propionic-2,2-d2 Acid (Standard) is a reference standard of Propionic-2,2-d2 Acid intended for quantitative analysis, quality control, and related biochemical research applications. Propionic-2,2-d2 acid is a deuterated compound of Propionic acid. Propionic acid has a CAS number of 79-09-4. Propionic acid (PA) is widely used as an antifungal agent in food. It is present naturally at low levels in dairy products and occurs ubiquitously, together with other short-chain fatty acids (SCFA), in the gastro-intestinal tract of humans and other mammals as an end-product of the microbial digestion of carbohydrates. It has significant physiological activity in animals. PA is irritant but produces no acute systemic effects and has no demonstrable genotoxic potential.Propionic aciduria is one of the most frequent organic acidurias, a disease that comprise many various disorders. The outcome of patients born with Propionic aciduria (genetic disorder) is poor intellectual development patterns, with 60% having an IQ less than 75 and requiring special education. Successful liver and/or renal transplantations, in a few patients, have resulted in better quality of life but have not necessarily prevented neurological and various visceral complications. These results emphasize the need for permanent metabolic follow-up whatever the therapeutic strategy. Decreased early mortality, less severe symptoms at diagnosis, and more favorable short-term neurodevelopmental outcome were recorded in patients identified through expanded newborn screening.
      • $611
      4-6 weeks
      Size
      QTY
    • Propionicacid-D5 (Standard)
      Propionic-D5 Acid (Standard)
      TMSM-606860153-92-6
      Propionicacid-D5 (Standard) is a reference standard of Propionicacid-D5 intended for quantitative analysis, quality control, and related biochemical research applications. Propionicacid-d5 is a deuterated compound of Propionicacid. Propionicacid has a CAS number of 79-09-4. Propionic acid (PA) is widely used as an antifungal agent in food. It is present naturally at low levels in dairy products and occurs ubiquitously, together with other short-chain fatty acids (SCFA), in the gastro-intestinal tract of humans and other mammals as an end-product of the microbial digestion of carbohydrates. It has significant physiological activity in animals. PA is irritant but produces no acute systemic effects and has no demonstrable genotoxic potential.Propionic aciduria is one of the most frequent organic acidurias, a disease that comprise many various disorders. The outcome of patients born with Propionic aciduria (genetic disorder) is poor intellectual development patterns, with 60% having an IQ less than 75 and requiring special education. Successful liver and/or renal transplantations, in a few patients, have resulted in better quality of life but have not necessarily prevented neurological and various visceral complications. These results emphasize the need for permanent metabolic follow-up whatever the therapeutic strategy. Decreased early mortality, less severe symptoms at diagnosis, and more favorable short-term neurodevelopmental outcome were recorded in patients identified through expanded newborn screening.
      • $210
      4-6 weeks
      Size
      QTY
    • 2-Methoxystypandrone
      TN277585122-21-0
      2-Methoxystypandrone displays an immunomodulatory effect in a cellular model, it blocks inflammatory responses by impairing NF-κB signaling to limit the inflammation and oxidative stress for preservation of BBB integrity. 2-Methoxystypandrone concomitant
      • $520
      Inquiry
      Size
      QTY